These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 25353342)
1. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342 [TBL] [Abstract][Full Text] [Related]
2. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Armstrong AJ Oncology (Williston Park); 2014 Oct; 28(10):881, 883. PubMed ID: 25323615 [No Abstract] [Full Text] [Related]
3. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis. Suzman DL; Antonarakis ES Oncology (Williston Park); 2014 Oct; 28(10):880, 882. PubMed ID: 25323614 [No Abstract] [Full Text] [Related]
4. [Docetaxel for metastatic prostate cancer: early is better]. Gietema JA; Oosting SF Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569 [TBL] [Abstract][Full Text] [Related]
5. Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta. García de Paredes Esteban JC; Alegre Del Rey EJ; Asensi Díez R Farm Hosp; 2017 Jul; 41(4):550-558. PubMed ID: 28683707 [TBL] [Abstract][Full Text] [Related]
7. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials. van Soest RJ; de Wit R BMC Med; 2015 Dec; 13():304. PubMed ID: 26695172 [TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348 [TBL] [Abstract][Full Text] [Related]
9. Should docetaxel be administered earlier in prostate cancer therapy? Graff JN; Beer TM Expert Rev Anticancer Ther; 2015; 15(9):977-9. PubMed ID: 26223224 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer. Davda R; Hughes S; Jones R; Crabb SJ; Troup J; Payne H Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):376-85. PubMed ID: 26874654 [TBL] [Abstract][Full Text] [Related]
12. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation. Xu L; Pachynski RK Curr Urol Rep; 2018 Aug; 19(10):79. PubMed ID: 30105573 [TBL] [Abstract][Full Text] [Related]
13. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M; Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877 [TBL] [Abstract][Full Text] [Related]
14. Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED. Aragon-Ching JB Asian J Androl; 2016; 18(3):444-5. PubMed ID: 26510505 [TBL] [Abstract][Full Text] [Related]
15. Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer. Tassinari D; Tamburini E; Gianni L; Drudi F; Fantini M; Santelmo C; Stocchi L; Montanari F; Sartori S Rev Recent Clin Trials; 2016; 11(4):317-323. PubMed ID: 27448518 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for metastatic castrate-sensitive prostate cancer. Miller RE; Sweeney CJ Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):139-44. PubMed ID: 26976365 [TBL] [Abstract][Full Text] [Related]
17. The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report. Rahman F; Rahardjo HE; Ariwicaksono SC; Hafizar H; Sembiring MGA; Andika R; Patandung R; Hidianingsih S; Hotasi SL Acta Med Indones; 2017 Jan; 49(1):74-78. PubMed ID: 28450658 [TBL] [Abstract][Full Text] [Related]
18. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Armstrong AJ; George DJ Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005 [TBL] [Abstract][Full Text] [Related]
20. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]